text_image
text_background
medium_height
UniServices Commercialisation
Printer Friendly, PDF & Email

Local Anaesthetic Implants

Categories for this Technology

Medical Device

Surgery

Anaesthesiology

 

Intellectual Property

Provisional Application

 

 

Seeking:

  • Partners/collaborators/investors to develop this technology further.

  • Out-licensing opportunities.

  • Feedback on the opportunity of this technology.

  • Advice on what additional data would you like to see to secure interest?

Summary

A novel mode of post-operation pain management in patients, utilising an implant imbued with a non-opioid analgesic.

 

Problems Addressed

Globally, more than 230 million surgical procedures are conducted every year and the most common method of post-operation severe pain management is the systemic administration of opiates. Opiate analgesics have negative side effects with growing concerns regarding abuse, in tandem with the slow recovery after surgery and major delays in patient mobilisation. Ultimately, this requires further intervention by healthcare professionals to manage patients recovery.

 

Technology

A novel drug delivery implanting method for the localised administration of a non-opioid analgesic drug into the peritoneal cavity ameliorates severe post-operation pains to enhance recovery. The implant has the potential to be made from a variety of polymer materials including radio-opaque polymers for imaging. The implant is loaded with the non- opioid analgesic drug, which is released to the site immediately following placement in the body, which can be achieved through a laparoscopic port. A range of polymer-drug compositions have been achieved with increased drug loading capacity to provide sustained release of drug with long-acting efficacy. The implants are stable with predictable drug release profiles.

Applications

Local anaesthetic implants with a non-opioid analgesic drug offers a potential substitution for post-operative severe pain management. The method could be particularly adapted for use in abdominal and thoracic surgery.

• Drug is formulated to be stable within the polymer, with no drug reservoir there is no risk of dose dumping

• Implants can be easily adapted to incorporate other drugs e.g. antibiotics or anti-inflammatories

• The drug formulation can also have application in surgical mesh, or bandages for external use

Advantages

• Recovery period is accelerated, and patients experience less discomfort throughout the process.

• The implant evenly distributes the analgesic drug along the site of surgery to ensure maximum therapeutic effect.

• The core-shell structure with the radio-opaque centre allows easy location and subsequent removal once the analgesia wears off.

• The non-opioid analgesic drug imposes no risks of addiction and abuse, removing the need for future intervention by healthcare professionals.

Inventors

Assoc. Professor Andrew Hill

 

Assoc. Professor Darren Svirskis

 

Questions about this Technology?

Contact Dr Sandhya Badrinarayanan